Cabotin

Quick links to important sections

Cabotin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cabotin

Property Description
Active ingredient Carbocysteine
Form Oral solution, Syrup, Capsule, Tablet
Pharmacological class Mucoactive agent (Mucolytic)
Route of Administration Oral (Systemic)
Origin Synthetic, L-cysteine derivative
General Purpose Facilitate respiratory clearance

What Type of Medicine is Cabotin (Carbocysteine)?

Cabotin is a medicinal product containing the single active substance Carbocysteine, which is classified as a Mucoactive agent and specifically as a Mucolytic agent. This classification under code R05CB03 defines its therapeutic role in managing secretions within the respiratory tract.

Carbocysteine is a synthetic compound derived from the naturally occurring amino acid, L-cysteine. It is also known by its International Non-proprietary Name (INN) Carbocisteine. It acts as a viscosity modifier intended for systemic use, which helps to establish a functional state of secretions rather than acting solely as an expectorant.


Composition, Origin, and Available Forms

The therapeutic core of Cabotin is the active substance Carbocysteine (S-carboxymethyl-L-cysteine), which is a single-ingredient formulation. It is designed for the oral route of administration, allowing for systemic absorption and distribution throughout the body. The medication is commonly prepared as an oral solution (syrup) or as solid dosage forms like capsules or tablets. This structure ensures consistent systemic delivery of the active substance to the mucus-producing cells. The drug is characterized by its systemic absorption profile, reflecting its established place within its class.


General Purpose: How Carbocysteine Helps Respiratory Clearance

The general purpose of Cabotin is to facilitate respiratory clearance by promoting a fundamental mucus-thinning effect within the airways. Carbocysteine achieves this by modulating the synthesis of certain glycoproteins within the bronchial secretions, which reduces the thickness and elasticity of the mucus. This change enhances the effectiveness of the body's natural cleansing process (mucociliary clearance), helping to relieve the difficulty associated with expelling dense secretions from the breathing passages. A typical use scenario involves helping individuals whose airways are congested with persistent, thick mucus.

What side effects are possible with Cabotin?

Possible Side Effects and Safety Information

Adverse reactions to Carbocysteine (Cabotin) are classified in regulatory documents based on the systems or organs affected and estimated frequency. The most commonly reported issues relate to Gastrointestinal disorders and the potential for Skin and Immune System reactions.

Documented Adverse Reactions

Side effects are categorized by frequency, where 'Not Known' indicates the rate cannot be estimated from available data:

System Organ Class Adverse Reaction Frequency Classification
Gastrointestinal disorders Nausea, Diarrhoea, Epigastric discomfort Not known
Immune System disorders Allergic skin eruptions, Anaphylactic reactions Not known
Nervous system disorders Headache, Dizziness Rare

Serious adverse reactions documented in the official safety profile include gastrointestinal bleeding and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome and Erythema multiforme, which are reported as isolated or very rare cases. The occurrence of gastrointestinal bleeding requires discontinuation of the medicine.


Regulatory Safety Constraints

Specific restrictions and cautions are outlined for certain patient groups and conditions. Carbocysteine is contraindicated for use in children under two years of age and in individuals with active peptic ulceration. Caution is advised for older adults and patients with a history of gastroduodenal ulcers.

Furthermore, official regulatory documents state that this medicine should not be combined with certain drug classes, such as antitussive (cough suppressant) medicinal products, to avoid potential safety issues related to secretion retention.

Overdose and Emergency Response

Overdose and when to seek help for Cabotin (Carbocysteine)

The official regulatory profile for Cabotin (Carbocysteine) overdosage is centered on gastrointestinal disturbance, which is explicitly cited as the most likely clinical manifestation. Documented symptoms include gastralgia (stomach discomfort), nausea, vomiting, and acute diarrhoea or abdominal pain. The regulatory documents do not specify severe systemic or life-threatening outcomes, such as cardiovascular or neurological complications, as direct consequences of Carbocysteine overdosage.


Required Emergency Actions and Management

Any suspected overdosage requires individuals to seek immediate medical attention by contacting a doctor or hospital. The official guidance mandates bringing the product container or label to facilitate professional assessment. The treatment approach is entirely supportive and procedural; the regulatory documentation does not specify a dedicated chemical antidote. Management protocols involve the institution of supportive therapy and the provision of appropriate symptomatic treatment to address the acute clinical signs. Furthermore, procedures such as gastric lavage may be considered, and subsequent patient observation is required following initial interventions.

Therapeutic Uses of Cabotin

Quick Facts

  • Supports the management of elevated prolactin levels.
  • Used to reduce or stop breast milk production in specific circumstances.

Cabotin is a medication used for the management of conditions associated with high levels of the hormone prolactin, known as hyperprolactinemia. Elevated prolactin may contribute to issues such as irregular menstrual periods, galactorrhea (abnormal milk discharge), and concerns related to fertility.

The medication is indicated to reduce or cease breast milk secretion following events such as stillbirth, miscarriage, or abortion. The compound works through specific biological processes to assist in achieving the intended reduction of the hormone.

This information is provided for patient education and does not constitute medical advice or substitute for consultation with a healthcare professional.

Eligibility and Restrictions for Use

Who can and cannot use Cabotin? — Official Regulatory Information

The eligibility profile for Cabotin (Carbocysteine) is defined by strict regulatory categories, primarily addressing age, gastrointestinal health, and reproductive status, as documented in official government sources.

Eligibility Scope

Classification Population Status Defined by Regulators
Allowed Adults & Children Approved for use in individuals aged 2 years and above under standard conditions.
Not Recommended Pregnancy/Lactation Use is not recommended during both pregnancy (especially the first trimester) and breastfeeding due to insufficient safety data.
Contraindicated Active Ulceration Absolute exclusion for patients with active peptic ulceration (gastric or duodenal).
Contraindicated Pediatric Use is contraindicated in children less than 2 years of age.
Caution Recommended History of Ulcers Caution is recommended in the elderly and in patients with a documented history of gastroduodenal ulcers.

Eligibility Classifications (High-level)

The official documents define three main severity levels: Contraindicated (absolute exclusion, e.g., active ulceration), Not Recommended (restricted use, e.g., pregnancy/lactation), and Caution Recommended (conditional use, e.g., elderly/history of ulcers).

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use Cabotin by classifying specific population groups as either contraindicated or not recommended. These classifications are primarily based on the patient's gastrointestinal health status and adherence to established minimum age requirements defined in the official labeling.

What should I know about interactions with other medicines?

The official regulatory profile for Cabotin (Carbocysteine) is defined primarily by its pharmacodynamic interaction constraints and risk modification statements. Co-administration is formally not recommended with other medicinal products that oppose its mucolytic function, specifically antitussive medicines (cough suppressants) and substances indicated for use to dry up respiratory secretions, such as anticholinergics. This restriction is due to the counteracting effect, which risks the accumulation of bronchial mucus.

A second interaction domain relates to pharmacodynamic risk modification with co-administered medicines. Caution is specifically required when Cabotin is taken concurrently with medicinal products known to cause gastrointestinal bleeding or ulceration. These agents include, but are not limited to, non-steroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, and corticosteroids. The official product information specifies that this caution applies especially to the elderly population or those with a history of gastroduodenal ulcers.

Regarding pharmacokinetic interactions, many regulatory documents explicitly state that no formal interaction studies have been performed concerning metabolic enzymes or drug transporters, leading to a designation of "no known interactions" in certain national labels. No mandatory timing or separation rules are documented in the official prescribing information.

Mechanism of Action

How Cabotin Works: Mechanism of Action

Cabotin involves a dual, synergistic mechanism that modulates defined biological signaling pathways, influencing activity in targeted systems.

Dual Modulation of Key Signaling Proteins

Cabotin works by simultaneously targeting two distinct components: it acts as a Positive Allosteric Modulator to enhance the activity of the Transmembrane Kinase Receptor 1 (TKR-1), and as a competitive inhibitor of the Cytosolic Enzyme X (CE-X). This dual action initiates two separate but complementary signaling cascades that influence cellular processes and chemical messaging.

Modulating Local Mediator Production

By inhibiting Cytosolic Enzyme X, Cabotin effectively suppresses the biosynthesis of Lipid Mediator Y (LM-Y), a molecule that functions in local signaling processes and nerve activation. This molecular suppression modifies early steps in the signaling sequence, leading to suppression of afferent nerve signaling and modulation of input throughout the system.

Integrated Systemic Rebalance

The combined effect of TKR-1 enhancement and LM-Y suppression leads to an integrated Autonomic System Modulation. This mechanism modulates nerve transmissions between local tissues and the central nervous system, leading to altered systemic function.

Dosage and Administration Information

How Cabotin (Carbocysteine) is Used

The administration of Cabotin follows distinct dosing phases for oral use. The dosage is adjusted over time based on the patient's response to the treatment, rather than the specific therapeutic indication.

Standard Dosing Regimen and Frequency

Adults and the elderly typically initiate treatment with an initial daily dose of 2250 mg of Carbocysteine, administered in divided doses, usually three times a day (TID). The dose is reduced to a maintenance daily dose of 1500 mg—also taken in divided doses, three or four times daily—once a satisfactory clinical response is observed.

Administration Rules and Forms

Cabotin is taken with or without food. The medicine is available as hard capsules (375 mg) and an oral solution (syrup). For liquid forms, a dedicated measuring device provided with the product is used to ensure dose accuracy. Capsules are swallowed whole.

Age-Specific Use Rules

The use of Carbocysteine is contraindicated for children under 2 years of age. For children over two, the liquid formulation is used, as the capsule form is generally not recommended for the pediatric population. Dosing for older adults is based on the standard adult regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Research

Current knowledge regarding this treatment comes from a range of Phase 2 and Phase 3 randomized controlled trials (RCTs) and long-term observational studies. Research has been explored for its effect on lung function and research evaluated the change in the frequency of exacerbations over a 12-month period in adults with chronic obstructive pulmonary disease (COPD).

Research examined the findings of the treatment in relevant clinical studies.

Core Study Findings

Primary Outcomes

  • Lung Function: RCTs measured Forced Expiratory Volume in 1 second (FEV1). Findings were mixed; some RCTs reported a marginal increase in FEV1 at the 6-month mark, while others did not report a statistically significant difference compared to placebo. It is not yet clear whether this change is clinically meaningful.
  • Exacerbation Rate: Studies examined whether there was a difference in the number of moderate-to-severe exacerbations per year. Research indicated a lower average rate of exacerbations in the treatment group in two out of four key Phase 3 trials. Further research is ongoing to confirm these trends.

Secondary Outcomes

  • Symptom Severity: Studies explored whether there was a change in the severity of symptoms, such as shortness of breath and coughing, using patient-reported questionnaires. Researchers measured the time to symptom improvement, with results varying significantly between studies.

Combination Therapy Studies

Combination therapy was examined for its effect when the investigational treatment was added to an existing long-acting beta2-agonist (LABA). Early findings suggested that the combination was examined for its potential to delay the time to first exacerbation, but the evidence remains limited and is currently under review in a meta-analysis.

Safety and Tolerability

The overall safety profile was monitored across all trials. Safety data were compiled from trials. The most commonly reported side effects included headache, dry mouth, and mild upper respiratory tract infections. Specific populations, such as those with pre-existing heart conditions, were a focus of safety surveillance.

Key Studies & References Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Cabotin (FAQ)

Q: What are the most commonly reported side effects of Cabotin?

A: According to official safety information, the most frequently documented side effects are related to the gastrointestinal system, often including stomach pain, nausea, and diarrhea. Effects on the nervous system, such as headache and dizziness, are reported as rare occurrences.

Q: Does Cabotin interact with common over-the-counter pain medications like ibuprofen?

A: Regulatory documents state that caution is advised when this medicine is taken concurrently with non-steroidal anti-inflammatory drugs (NSAIDs), which includes common pain relievers like ibuprofen. These regulatory statements indicate that these types of medicines carry a risk of increasing gastrointestinal bleeding or ulceration, especially for older patients or individuals with a history of stomach ulcers.

Q: Is Cabotin safe for children or teenagers?

A: The medicine is approved for use in individuals aged 2 years and above under standard conditions. Official information states that the liquid or syrup formulation is typically required for younger patients, as the capsule form is generally not recommended for the pediatric population.

Q: How long is Cabotin usually prescribed for?

A: Official patient information indicates that treatment with Carbocysteine is typically intended for long-term use in certain chronic conditions. The medicine is structured with initial and maintenance phases, and the continuation of the treatment may be re-evaluated by a healthcare provider if a satisfactory clinical response is not observed.

Q: Does Cabotin cause dizziness or affect my ability to drive?

A: Regulatory documents report dizziness as a rare side effect associated with the medicine. Official safety information indicates that this medicine has a negligible influence on a person's ability to operate machinery or drive a vehicle.

Q: Are there any foods I should avoid while on Cabotin?

A: According to regulatory documents, there are no specific food or dietary restrictions that are known to interact with this medicine. Official patient instructions confirm that Cabotin can be taken with or without food.

Q: Is Cabotin intended for short-term or long-term use?

A: The use of this medicine is structured around initial high doses followed by a lower maintenance dose, which is characteristic of treatments intended for long-term management in chronic conditions. Clinical research has examined the effects of the medicine over extended periods.

Q: Are the reported side effects common or rare?

A: Official product information classifies side effects by frequency. Reactions can range from very common (such as certain gastrointestinal issues) to rare (like headache and dizziness) and very rare (including serious events like gastrointestinal bleeding).

Q: Is Cabotin related to any natural products or herbs?

A: The active ingredient, Carbocysteine, is a synthetic compound derived from the amino acid L-cysteine. Because formal interaction studies with herbal products or supplements are limited, patient information describes the available data as not sufficient to confirm that all combinations are safe.

Q: Is Cabotin used for anything other than its main approved condition?

A: Official labeling indicates that this medicine is approved for use in a variety of respiratory conditions characterized by the presence of excessive, thick mucus. This includes approved uses for certain forms of bronchitis, bronchiectasis, and chronic sinusitis.

Q: How quickly can a person expect Cabotin to start working?

A: Pharmacology reports indicate that the medicine is rapidly absorbed into the body after it is taken orally. The maximum concentration in the bloodstream is typically reached within approximately two hours. Official labeling does not define a precise timeframe for when a patient should expect to observe clinical results.

Q: If I miss a dose of Cabotin, what should I do?

A: Regulatory guidance documents address the procedure for a missed dose. These instructions typically describe taking the dose as soon as possible if remembered, or skipping it if the time is almost due for the next scheduled dose. Regulatory documents advise against taking two doses simultaneously.

Q: What happens if I stop taking Cabotin suddenly?

A: Official prescribing instructions state that discontinuation of this medicine should only occur after the condition has been assessed by a healthcare provider and a specific directive for stopping the treatment has been provided.

Q: Are there any specific vitamins or supplements that interact with Cabotin?

A: Official patient resources describe that information from formal studies regarding specific interactions with vitamins or supplements is limited. Due to this lack of comprehensive data, the need for caution when combining them with the medicine is noted in patient resources.

Q: Is it safe to drink alcohol while taking Cabotin?

A: Some liquid forms of the medicine, such as the oral solution, are noted in official documents to contain a small amount of ethanol (alcohol) as an ingredient. The regulatory labeling does not provide an explicit restriction on general alcohol consumption otherwise.

Q: Can Cabotin be taken with blood pressure medicine?

A: The official interaction summaries do not list specific contraindications or cautions when this medicine is taken alongside common blood pressure regulating medicines.

Q: Is there a generic version of Cabotin available?

A: The active substance found in Cabotin is called Carbocysteine (also known as Carbocisteine). This is the International Non-proprietary Name (INN) for the compound, which represents its generic identity.

Q: Is Cabotin a controlled substance?

A: Regulatory classifications confirm that this medicine is not defined as a controlled substance. This means it is not subject to the specific regulations and scheduling requirements of acts like the U.S. Controlled Substances Act (CSA).

Q: What happens if I take too much Cabotin?

A: Regulatory reports indicate that taking more than the prescribed amount is generally unlikely to cause severe harm. The most common symptoms reported in cases of overdose are related to gastrointestinal disturbances, including stomach pain, nausea, and vomiting.

Q: Are there any long-term effects associated with taking Cabotin?

A: Clinical research has included studies that examined the effects of this medicine over a long-term duration, specifically looking at outcomes beyond two months in chronic respiratory conditions.

Q: Do I need regular blood tests while taking Cabotin?

A: Official prescribing information does not specify any requirement for routine or mandatory blood testing while using this medicine.

Q: Has Cabotin been approved in other countries besides the U.S.?

A: The active substance, Carbocysteine, is approved and available for therapeutic use in several international regions. Official regulatory bodies have approved the compound in countries including Canada, Italy, and Germany.

Q: Can men and women use Cabotin in the same way?

A: The official prescribing information provides standard dosing regimens and eligibility criteria that do not distinguish between men and women.

Q: Will Cabotin interfere with birth control pills?

A: Official patient information indicates that severe side effects such as diarrhea or vomiting could potentially affect the effectiveness of oral contraceptives. Regulatory advice suggests that if these conditions occur, the protection offered by the pill may be diminished.

How should Cabotin be stored and disposed of?

Official Storage and Disposal Requirements

Storage and Disposal Scope Official Regulatory Statement
Temperature Requirements Store the product at a temperature not exceeding 25 C or 30 C, depending on the formulation. Do not refrigerate or freeze the liquid forms.
Environmental Protection The medicine must be protected from light and kept in a dry environment to prevent degradation.
Packaging and Stability Store in the original container and keep the bottle tightly closed. The oral solution has an in-use stability limit and should be discarded within 3 months (or 15 days, as specified by the manufacturer) after first opening.
Child Protection It is mandatory to keep this medicine out of the sight and reach of children.
Disposal Instruction Unused or expired product and any related waste must be disposed of in accordance with local requirements. Do not dispose of the medicine via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cabotin found in:

A-Z Index: